However, unlike EGFR and HER2, HER3 remains a challenging therapeutic target; hence, with the exception of the recently approved bispecific antibody targeting both HER2 and HER3 discussed above (see Section 2.2.2), there is no clinically approved HER3-specific mAb for the treatment of cancer patients [128,129,210]. Here, ERBB2 is linked to cancer.